AI-guided care for wet age-related macular degeneration
Part of Eyes & vision clinical trials.
This Phase 4 study tests an artificial-intelligence (AI) system used in real-world care for people with “wet” age-related macular degeneration. The goal is to help doctors monitor and treat the eye more accurately and safely over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 50 or older.
- You have active wet age-related macular degeneration in the study eye (confirmed with eye imaging tests).
- Your vision in the study eye must be at least 20/200 (a score of 0.1 or better).
- You do NOT have major scarring or age-related “atrophy” that involves the center of the vision (the fovea).
- You can attend all study visits and follow study eye procedures; you will sign consent.
- You have not had certain recent eye surgeries (like eye surgery within the last 3 months, or specific cataract/glaucoma/transplant surgeries within the last 6–12 months).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses artificial intelligence to track changes in the eyes of people with advanced age-related macular degeneration (AMD) that has caused a specific type of damage (atrophy) in the retina. The goal is to see if AI can help detect when the disease gets worse, so doctors can personalize monitoring for each patient.
This study uses artificial intelligence to track changes in the eyes of people with early or intermediate age-related macular degeneration (AMD). It aims to better understand how the disease progresses and may help doctors personalize care.
This study looks at whether certain proteins or molecules in the jelly-like fluid inside the eye can predict why some people with wet age-related macular degeneration do not respond well to standard anti-VEGF injections. By studying these signals, researchers hope to improve future treatment and better tailor care to individual patients.
This study tests an eye drop solution designed to treat wet age-related macular degeneration (AMD), a condition that causes blurry vision due to abnormal blood vessel growth. The treatment aims to reduce fluid and improve vision without the need for frequent eye injections.
This study tests a new medicine called IBI302 for wet age-related macular degeneration (AMD). It aims to slow vision loss by targeting both blood vessel growth and inflammation. You might qualify if you have active wet AMD and have not had certain injections recently.
This trial tests a new medicine called VIS-101, given as an injection into the eye, for people with wet age-related macular degeneration (AMD) who have not been treated before. The goal is to see if it can reduce fluid buildup and improve vision while being safe.
Hear when a new Exudative Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.